227617-16-5

Usage

Structure

Ethyl ester derivative of pyrazolo[3,4-b]pyridine-5-carboxylic acid, with a chlorine atom and a 4-methoxyphenylmethyl group attached to the pyrazole ring

Usage

Pharmaceutical research and drug development, potential therapeutic applications, potential as a therapeutic agent for various conditions, possible applications in agrochemicals and materials science

Biological activities

Not fully elucidated

Pharmacological properties

Not fully elucidated

Upstream product

• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 3528-45-8 1-(4-methoxybenzyl)-1H-pyrazol-5-amine 
• 227617-15-4 4-Hydroxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 

Downstream Products

• 227617-17-6 4-Butoxy-1-[(4-methoxyphenyl)methyl]-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 1086423-59-7 ethyl 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b] pyridine-5-carboxylate 
• 1203662-63-8 4-(2-fluoro-4-iodophenylamino)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl ester 
• 1453175-13-7 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 4-(4-pyrrolidin-1-ylpiperidine-1-sulfonyl)benzylamide 
• 952182-02-4 1H-pyrazolo[3,4-b] pyridine-5-carboxylic acid 
• 1453176-76-5 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid benzylamide 
• 1453176-77-6 4-{[(1H-pyrazolo[3_,4-b]pyridine-5-carbonyl)amino]methyl}benzenesulfonyl chloride 
• 1453174-45-2 1H-pyrazolo[3,4-b]pyridine-5-carboxyIic acid 4-(1-acetylpiperidine-4-sulfonyl)benzylamide 
• 1086423-60-0 1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid 
• 1086423-58-6 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide 
• 1086423-61-1 1-(4-methoxy-benzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid [2-methyl-5-(3-trifluoromethyl-benzoylamino)-phenyl]-amide 
• 1620012-22-7 ethyl 4-{(3S)-3-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylate 
• 1620012-20-5 5-amino-N-{4-[(3S)-3-aminopiperidin-1-yl]-1H-pyrazolo[3,4-b]pyridin-5-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620012-25-0 tert-butyl {(3S)-1-[5-amino-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-b]pyridin-4-yl]piperidin-3-yl}carbamate 

Relevant academic research and scientific papers

AMIDO-BENZYL SULFONE AND SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

AMIDO-BENZYL SULFONE AND SULFONAMIDE DERIVATIVES

Disclosed are certain amido-benzyl sulfone and sulfonamide compounds, pharmaceutical compositions comprising such compounds, land methods of treatment using such compounds.

PYRIDINYL AND PYRIMIDINYL SULFOXIDE AND SULFONE DERIVATIVES

Disclosed are certain pyridinyl and pyrimidinyl sulfoxide and sulfone compounds, pharmaceutical compositions comprising such compounds and methods of treatment using such compounds.

ALKYL-AND DI-SUBSTITUTED AMIDO-BENZYL SULFONAMIDE DERIVATIVES

The present invention relates to certain alkyl- and di-substituted amido-benzyl sulfonamide compounds, pharmaceutical compositions comprising such compounds, and to methods of treatment of NAMPT-mediated disorders, such as diabetes, rheumatoid arthritis,

AMIDO SPIROCYCLIC AMIDE AND SULFONAMIDE DERIVATIVES

Provided are amido spirocyclic amide and sulfonamide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5- carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Potent, 1H-pyrazolo[3,4-b]pyridine-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using structure-based design techniques. Many of these compounds exhibited nanomolar antiproliferation activities a

AMIDO-BENZYL SULFOXIDE DERIVATIVES

The present invention relates to certain amido-benzyl sulfoxide compounds, pharmaceutical compositions comprising such compounds, and methods of treatment of an NAMPT-mediated disease or condition in a subject, selected from solid or liquid tumor, rheumat

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK, C-kit, c-RAF, CSK, c-SRC, EGFR, Fes, FGFR3, Flt3, Fms, Fyn, IGF-1R, IR, JAK(2), JAK(3), KDR, Lck, NLK, p70S6K, PDGFRα, Ros, SAPK2α, SGK, SIK, Syk, Tie2 and TrkB kinases.

PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF

The invention provides compounds of formula (l) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, CSK, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRalpha, PDGFRbeta, PKCalpha, SAPK2alpha, Src, SIK, Syk, Tie2 and TrkB kinases.

PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS

The present invention relates to phosphodiesterase (PDE) type 4, phosphodiesterase (PDE) type 7 and dual PDE type 4 /PDE type 7 inhibitors. Compounds disclosed hereinf having the structure of Formula 1: can be useful in the treatment, prevention, inhibiti